Therapy Areas: Cardiovascular
RDD Pharma names new chairman of the board of directors
5 June 2018 -

RDD Pharma, a specialty pharma company focused on innovative therapies for anorectal diseases and gastrointestinal disorders, announced yesterday that the company has named Dr Mark Sirgo as its chairman of the board of directors.

Dr Sirgo's experience with public company leadership from development stage to commercial enterprise brings additional value to the present Board's expertise and experience. He is an executive leader with more than 30 years of pharmaceutical industry experience including the past 13 years as CEO of BioDelivery Sciences. Under his leadership, BDSI went from a preclinical stage to a fully integrated commercial enterprise following the FDA approval of three products during this period. Prior to BDSI, Dr Sirgo spent 17 years at Glaxo, Glaxo Wellcome and GSK in the areas of gastrointestinal, cardiovascular, and respiratory drug development. His career includes six years in sales and marketing including the management of global sales and marketing for PPD, a contract research organisation. He has also served on several public company boards including Salix Pharmaceuticals until its sale in 2015.

Jason Laufer, CEO of RDD Pharma, said, 'We welcome Mark to our board of directors as we move to a company with late clinical stage assets and a growing development pipeline. Mark's experience and insights in the gastrointestinal and OTC arenas will be extremely valuable as our products head forward to commercialisation.'

'I am excited to lead the RDD Pharma board of directors,' said Dr. Sirgo. +ACI-RDD is occupying a therapeutic space with clear unmet need and limited products in development to address patients' needs with a pipeline focused on under-served indications such as chronic anal fissure, fecal incontinence, radiation colitis and pruritus ani.'

Login
Username:

Password: